Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?

Lena Specht; John Raemaekers; Lena Specht; John Raemaekers

doi:10.1016/j.hoc.2007.07.002

Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?

Lena Specht, John Raemaekers, Lena Specht, John Raemaekers

3 Citationer (Scopus)

Abstract

The outcome of patients who have early unfavorable or intermediate-stage Hodgkin's lymphoma has greatly improved. The increasing efficacy of chemotherapy and late toxic effects of wide-field radiotherapy justify the careful testing of the new involved-node radiotherapy principle in the combined-modality approach. For the purpose of tailoring treatment to the individual patient we need more accurate measures, preferably predictive factors that may tell us how the individual patient should be treated. The result of an early positron emission tomography scan with fluorodeoxyglucose may well become the major new treatment-related guidance for an individually tailored treatment approach.

Originalsprog	Engelsk
Tidsskrift	Hematology/Oncology Clinics of North America
Vol/bind	21
Udgave nummer	5
Sider (fra-til)	881-96
Antal sider	16
ISSN	0889-8588
DOI	https://doi.org/10.1016/j.hoc.2007.07.002 https://doi.org/10.1016/j.hoc.2007.07.002
Status	Udgivet - 1 okt. 2007

Adgang til dokumentet

Citationsformater

@article{4d2414304c7c11df928f000ea68e967b,

title = "Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?",

abstract = "The outcome of patients who have early unfavorable or intermediate-stage Hodgkin's lymphoma has greatly improved. The increasing efficacy of chemotherapy and late toxic effects of wide-field radiotherapy justify the careful testing of the new involved-node radiotherapy principle in the combined-modality approach. For the purpose of tailoring treatment to the individual patient we need more accurate measures, preferably predictive factors that may tell us how the individual patient should be treated. The result of an early positron emission tomography scan with fluorodeoxyglucose may well become the major new treatment-related guidance for an individually tailored treatment approach.",

author = "Lena Specht and John Raemaekers and Lena Specht and John Raemaekers",

note = "Keywords: Disease Progression; Hodgkin Disease; Humans; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic",

year = "2007",

month = oct,

day = "1",

doi = "10.1016/j.hoc.2007.07.002",

language = "English",

volume = "21",

pages = "881--96",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",